SYSTEMATIC REVIEW AND META-ANALYSIS

Omega-3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials

Xin Zhang, PhD*; Jennifer A. Ritonja, PhD*; Na Zhou, PhD; Bingshu E. Chen ២, PhD; Xinzhi Li ២, MD, PhD

BACKGROUND: Current evidence might support the use of omega-3 fatty acids (preferably docosahexaenoic acid and eicosapentaenoic acid) for lowering blood pressure (BP), but the strength and shape of the dose-response relationship remains unclear.

METHODS AND RESULTS: This study included randomized controlled trials published before May 7, 2021, that involved participants aged \geq 18 years, and examined an association between omega-3 fatty acids (docosahexaenoic acid, eicosapentaenoic acid, or both) and BP. A random-effects 1-stage cubic spline regression model was used to predict the average dose-response association between daily omega-3 fatty acid intake and changes in BP. We also conducted stratified analyses to examine differences by prespecified subgroups. Seventy-one trials were included, involving 4973 individuals with a combined docosahexaenoic acid+eicosapentaenoic acid dose of 2.8 g/d (interquartile range, 1.3 g/d to 3.6 g/d). A nonlinear association was found overall or in most subgroups, depicted as J-shaped dose-response curves. The optimal intake in both systolic BP and diastolic BP reductions (mm Hg) were obtained by moderate doses between 2 g/d (systolic BP, -2.61 [95% CI, -3.57 to -1.65]; diastolic BP, -1.64 [95% CI, -2.29 to -0.99]) and 3 g/d (systolic BP, -2.61 [95% CI, -3.52 to -1.69]; diastolic BP, -1.80 [95% CI, -2.38 to -1.23]). Subgroup studies revealed stronger and approximately linear dose-response relations among hypertensive, hyperlipidemic, and older populations.

CONCLUSIONS: This dose-response meta-analysis demonstrates that the optimal combined intake of omega-3 fatty acids for BP lowering is likely between 2 g/d and 3 g/d. Doses of omega-3 fatty acid intake above the recommended 3 g/d may be associated with additional benefits in lowering BP among groups at high risk for cardiovascular diseases.

Key Words: docosahexaenoic acid = eicosapentaenoic acid = hypertension = long-chain fatty acids = 1-stage regression

See Editorial by George et al.

pidemiologic and experimental studies indicate that omega-3 polyunsaturated fatty acids (ω 3 PUFAs), preferably including docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may have cardiovascular health benefits by reducing modifiable

risk factors. For example, intake of EPA was associated with reduced risks of major vascular events in JELIS (Japan Eicosapentaenoic Acid Lipid Intervention Study)¹ and REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial).²

*X. Zhang and J. A. Ritonja contributed equally.

JAHA is available at: www.ahajournals.org/journal/jaha

Correspondence to: Bingshu E. Chen, PhD, Canadian Cancer Trials Group and Department of Public Health Sciences, Queen's University, 10 Stuart Street, Kingston, ON K7L 3N6, Canada. Email: bechen@ctg.queensu.ca; Xinzhi Li, MD, PhD, School of Pharmacy and State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Room 213D, Block E, Avenida Wai Long, Taipa, Macau, 999078, China. Email: xizli@must.edu.mo

Supplemental Material for this article is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.121.025071

For Sources of Funding and Disclosures, see page 11.

^{© 2022} The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

CLINICAL PERSPECTIVE

What Is New?

- Intake of omega-3 fatty acids has a nonlinear association with reductions in blood pressure.
- The optimal daily intake of omega-3 fatty acid for blood pressure control appears to be 3 g.

What Are the Clinical Implications?

 An optimal dose of omega-3 fatty acids is potentially needed for blood pressure control in the general population, but individuals who are at high risk of developing cardiovascular diseases may benefit from higher doses.

Nonstandard Abbreviations and Acronyms

DBP DHA EPA	diastolic blood pressure docosahexaenoic acid eicosapentaenoic acid
JELIS	Japan Eicosapentaenoic Acid Lipid Intervention Study
REDUCE-IT	Reduction of Cardiovascular Events With Icosapent Ethyl– Intervention Trial
SBP	systolic blood pressure
ω 3 PUFA	omega-3 polyunsaturated fatty acid

However, recently completed clinical studies and meta-analyses^{5,6} showed that supplementation of ω 3 PUFAs did not offer significant favorable impacts on cardiovascular events, such as the risk of cardiovascular disease, myocardial infarction, or stroke. Previous meta-analyses have also examined the association between ω 3 PUFA intake and blood pressure (BP),⁷⁻¹¹ but have been unable to reveal a significant dose-response relationship^{8,10,12} or have shown conflicting trends.^{7,11} These past meta-analyses examined the dose-response relationship using pooled meta-regression^{8,10} or, by grouping categories of exposure into separate meta-analyses,^{7,11} approaches that are prone to biases and do not take into account the correlations among effects at different dose levels.¹³

These limitations warrant further examination of the effects of ω 3 PUFAs on changes in BP among randomized controlled trials (RCTs). To fully capture the dose-response effect and reflect heterogeneity among the studies, we utilized a 1-stage cubic spline regression model, recently developed¹³ and used for dose-response meta-analyses in 2 BP systematic reviews.^{14,15} The 1-stage spline mixed model is advantageous since it allows estimation of nonlinear dose-response curves, including J or L shape, and allows for the inclusion of studies with <3 exposure levels, in comparison to 2-stage methods.¹³ Following a comprehensive literature review for RCTs, this study aimed to more precisely characterize the dose-response effect of ω 3 PUFAs (DHA, EPA, or both) on BP in the general population and relevant subgroups.

METHODS

The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for the conduct of meta-analysis of randomized trials and a checklist was attached (Table S1). The data that support the findings of this study are available from the corresponding author on reasonable request. This meta-analysis was performed with the previously published trials. Therefore, ethical review or institutional review board approval was not applicable.

Literature Review

A systematic literature search was conducted for articles published before May 7, 2021, using PubMed and Embase databases (Table S2). Manual searches were undertaken to screen the reference lists of relevant studies, reviews, and meta-analyses for additional studies. Two reviewers (X.Z. and X.L.) screened each study independently and discrepancies were resolved through discussion. The prespecified eligibility criteria were parallel or crossover RCTs that examined the association between intake of DHA/EPA (combined or individual) and systolic BP (SBP) and/or diastolic BP (DBP) in adults (aged ≥18 years). Studies were eligible if they examined intake of DHA/EPA through diet or fatty oil supplementation. We excluded trials in which: (1) concurrent inactive placebo controls were lacking; (2) intervention duration was <4 weeks; (3) a washout period of <4 weeks was applied between treatments in crossover trials; (4) patients with hypertension received concurrent BP-lowering medications^{11,12}; and (5) studies were conducted in pregnant and nursing women, or individuals with preexisting cardiovascular events (eg, those with myocardial infarction or heart failure), renal diseases, or secondary hypertension. Assessment of the methodological quality was performed independently using the Cochrane risk-of-bias tool 2.16

Data Extraction

For each eligible study, information was extracted independently by 2 of the authors (N.Z. and X.Z.) and confirmed by a third author (X.L.) using a standardized form. The effects of each dose of exposure were extracted individually in our study. In experiments with multiple follow-up time points, only changes in SBP and DBP levels at the end of the treatment versus pretreatment were extracted, avoiding multiple measurements from the same trial. If an SD was not provided directly, we calculated it from the SE, interquartile range, or CI.¹⁷

Exposure and Outcome Assessment

Most studies that examined the effects of omega-3 fatty acids used a combined supplementation of EPA and DHA. The exposure levels were expressed by DHA+EPA combined or DHA/EPA alone. For intake of DHA/EPA through diet, the exposure level was determined by the fraction of pure DHA/EPA amount over the food consumed daily. For fatty oil supplementation trials, the exposure level was determined by the pure DHA/EPA content as claimed by the researchers or the manufacturers. We determined the net mean difference in BP (Δ BP_{between}) between the exposure levels of each RCT as the difference at the end of the intervention minus the corresponding pretreatment value (Δ BP_{intragroup}).

Publication Bias Assessment

Publication bias was examined visually using funnel plots to assess the SE as a function of effect size, and performing Egger regression test to examine small-study bias using R *metafor* functions.¹⁸ We also used the trim-and-fill method to estimate the number of potential missing studies caused by publication bias. A leave-one-out strategy was applied for sensitivity analyses, where we repeatedly ran the dose-response analysis to assess the missing study's influence on overall mean BP change.

Dose-Response Analysis

The placebo dose (0 g/d) was used as the reference for all analyses. A 1-stage random-effects doseresponse model¹³ was performed to predict the average dose-response relationship between administration of DHA+EPA and changes in SBP and DBP levels. We tested the linearity assumption underlying the dose-response relationship by fitting a restricted cubic spline model with 3 knots (10th, 50th, and 90th percentiles) of the doses.¹⁹ Included studies were pooled into a continuous dose-response curve, and then the predicted effect of omega-3 on BP was estimated from the curve at given doses (ie, 1 g/d, 2 g/d, 3 g/d, 4 g/d, and 5 g/d). Additionally, subgroup analyses were conducted by stratifying studies according to study design (crossover versus parallel), hypertension (SBP ≥140 mm Hg or DBP ≥90 mm Hg), or hyperlipidemia (total cholesterol ≥200 mg/dL or triglycerides ≥150 mg/dL) status, intervention (supplementation versus diet), exposure composition (fish oil versus purified ethyl ester), duration of treatment (≥12 weeks or not), sex, and average age (≥45 years or <45 years). We also conducted subgroup analyses by baseline SBP (≥130 mm Hg versus <130 mm Hg), according to the new cut point suggested in a recent American Heart Association hypertension guideline.²⁰ The 1-stage cubic spline regression model was conducted using the *dosresmeta* R packages (https://github.com/alecr i/dosresmeta).^{13,21,22}

RESULTS

Study Characteristics

After removing duplicates, the systematic search retrieved 3066 relevant articles. The title and abstract review further excluded 2897 articles. Full-text examination of 169 articles yielded 71 eligible RCTs (references 23 and 24 and references 36 to 104 in the Supplemental Material) that were included in the analyses. A PRISMA flow diagram of the literature screening is shown in Figure 1. Study characteristics of the included trials are shown in Table S3. These trials, published between 1987 and 2020, reported an overall sample size of 4973 participants with an average age between 22 to 86 years. A parallel design was adopted predominantly in 60 trials, and only 11 trials used a crossover design. These trials were conducted in Europe (n=27), North America (n=25), Oceania (n=16), and Asia (n=3). More than a half of the trials (43 of 71) included both men and women, whereas 25 included only men and 3 included only women. Most trials were restricted to participants without hypertension (n=56 [79%], average baseline SBP <140 mm Hg) and without hyperlipidemia (n=57 [80%], average total cholesterol<200 mg/dL [5.2 mmol/L] and triglycerides <150 mg/dL [1.7 mmol/L]). In terms of outcome measurement, BP was measured either manually (n=13), automatically (n=44), or not reported (n=14), in ambulatory (n=5), rest (n=8), seated (n=32), supine (n=12), or unknown (n=14) modalities. The average intervention duration was 10 weeks (interguartile range, 6–12 weeks) (Figure S1A), and the duration was longer than 12 weeks (ranging from 12 to 52 weeks) in 29 trials and <12 weeks in 42 trials. In the majority of studies (n=64), interventions of supplementation were accomplished by capsuled fish oil, algal oil, or purified fish oil ethyl esters. The remainder of studies (n=7) used a dietary intervention that included intake of fish meals (eg, mackerel, salmon, trout, and tuna) and other fish oilfortified foods, either cooked at home or by a dietitian. The most commonly used placebo was olive oil, along with the remainder consisting of types of vegetable oils, such as safflower, sunflower, corn, soybean, and palm oils. Fifty-three of 71 trials reported the combined effects of DHA and EPA, with an average combined dose of 2.8 g/d (interquartile range, 1.3-3.6; range 0.2-15




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of systematic literature search and screening for randomized controlled trials published through May 2021 that met the study inclusion and exclusion criteria. DHA indicates docosahexaenoic acid; and EPA, eicosapentaenoic acid.

g/d) (Figure S1B), DHA dose of 1.4 g/d (range, 0 to 6 g/d), and EPA dose of 1.8 g/d (range, 0 to 9 g/d); only 11 and 6 trials observed the effects of individual DHA or EPA, respectively.

Overall Dose-Response Analysis

The Table summarizes the impact of combined doses of DHA+EPA at 1 g/d, 2 g/d, 3 g/d, 4 g/d, and 5 g/d on average changes in BP, compared with the placebo or control group (combined dose=0 g/d). We found a significant nonlinear dose-response relationship for both SBP and DBP models (Figure 2) (z=3.87 [P=0.0001])and z=2.68 [P=0.0073], respectively). The J-shaped curves suggest that dosages of DHA+EPA at 2 g/d to 3 g/d are associated with the strongest changes in both SBP and DBP relative to the reference dose (0 g/d). The estimated average dose-response curves and corresponding CIs also indicate that the dose region of apparent improvement for SBP and DBP is from 0 g/d to 5 g/d. When compared with the reference (0 g/d), the average mean changes in SBP were -2.61 mm Hg (95% Cl, -3.57 to -1.65) for 2 g/d of DHA+EPA, and -2.61 mm Hg (95% Cl, -3.52 to -1.69) for 3 g/d of DHA+EPA. The average mean changes in DBP were -1.64 mm Hg (95% Cl, -2.29 to -0.99) for 2 g/d of DHA+EPA, and –1.80 mm Hg (95% Cl, –2.38 to –1.23) for 3 g/d of DHA+EPA (Table). In both SBP and DBP models, combined doses >3 g/d were associated with weaker or null changes in BP (Table). The width of the Cls was wider at exposure levels >6 g/d for both SBP and DBP. Only 2 trials^{23,24} examined a dose >7 g/d (specifically, at 15 g/d). Removal of these 2 trials did not change the shape of the dose-response curve, despite the narrower Cls (Figure S2).

Subgroup Analyses


For studies including an average baseline SBP of \geq 130 mm Hg, we found evidence that DHA+EPA supplementation had an approximately linear trend with BP, where increasing supplementation resulted in stronger reductions in SBP and DBP (Figure 3, Table). This trend was not evident among those with a baseline SBP of <130 mm Hg, although a similar optimal intake of 2 g/d to 3 g/d as our original findings was found. Similar findings were also seen when stratified by hypertension status (SBP \geq 140 mm Hg, as defined in most included trials), where patients with hypertension showed greater reductions in SBP and DBP, compared with those without hypertension (Table, Figure S3). When stratifying by the presence of hyperlipidemia, we found


Consumption and BP Reduc
DHA+EPA
Between
Relationship
se-Response
Average Dos
. Estimated
<u>e</u>

			1.0 g/d		2.0 g/d		3.0 g/d		4.0 g/d		5.0 g/d	
BP	Participants	No*	Ш	(95% CI)	MD	(95% CI)	MD	(95% CI)	MD	(95% CI)	MD	(95% CI)
SBP	AII	20	-1.81	(-2.52 to -1.10)	-2.61	(-3.57 to -1.65)	-2.61	(-3.52 to -1.69)	-2.15	(-3.08 to -1.22)	-1.57	(-2.79 to -0.34)
DBP	All	69	-1.07	(-1.57 to -0.57)	-1.64	(-2.29 to -0.99)	-1.80	(-2.38 to -1.23)	-1.73	(-2.27 to -1.19)	-1.59	(-2.34 to -0.84)
Baseline SBP, mm Hg	, mm Hg											
SBP	≥130	19	-1.53	(-2.67 to -0.40)	-2.57	(-4.32 to -0.81)	-3.22	(-5.21 to -1.23)	-3.62	(-5.64 to -1.59)	-3.88	(-5.88 to -1.88)
	<130	44	-1.73	(-2.72 to -0.75)	-2.38	(-3.62 to -1.13)	-2.20	(-3.29 to -1.10)	-1.65	(-2.79 to -0.51)	-1.07	(-2.65 to 0.51)
DBP	≥80	19	-1.46	(-2.14 to -0.78)	-2.49	(-3.58 to -1.40)	-3.18	(-4.48 to -1.87)	-3.64	(-5.03 to -2.25)	-3.99	(-5.41 to -2.58)
	<80	45	-0.83	(-1.50 to -0.16)	-1.31	(-2.13 to -0.49)	-1.54	(-2.21 to -0.87)	-1.66	(-2.36 to -0.95)	-1.76	(-2.83 to -0.69)
ypertension	Hypertension status, SBP ≥140 mm Hg or DBP ≥90 mm Hg	g or DBP	≥90 mm H	ß								
SBP	Hypertension	16	-2.56	(-3.46 to -1.65)	-3.99	(-5.29 to -2.70)	-4.54	(-6.02 to -3.05)	-4.42	(-6.33 to -2.52)	-3.89	(-6.62 to -1.16)
	No hypertension	55	-1.66	(-2.52 to -0.80)	-2.22	(-3.30 to -1.14)	-1.97	(-2.90 to -1.03)	-1.35	(-2.32 to -0.39)	-0.70	(-2.06 to 0.66)
DBP	Hypertension	16	-1.23	(-1.90 to -0.55)	-2.14	(-3.25 to -1.03)	-2.81	(-4.18 to -1.45)	-3.30	(-4.80 to -1.81)	-3.68	(-5.25 to -2.10)
	No hypertension	55	-0.94	(-1.55 to -0.33)	-1.42	(-2.18 to -0.67)	-1.57	(-2.18 to -0.95)	-1.55	(-2.15 to -0.96)	-1.53	(-2.41 to -0.64)
/perlipidemi	Hyperlipidemia status, total cholesterol ≥200 mg/dL or triglycerides ≥150 mg/dl	l ≥200 m	g/dL or trig	llycerides ≥150 mg/dL								
SBP	Hyperlipidemia	4	-1.84	(-3.00 to -0.69)	-3.17	(-4.82 to -1.52)	-3.78	(-5.21 to -2.35)	-4.03	(-5.65 to -2.41)	-4.24	(-6.75 to -1.73)
	No hyperlipidemia	56	-1.68	(-2.52 to -0.84)	-2.36	(-3.50 to -1.21)	-2.26	(-3.35 to -1.17)	-1.72	(-2.73 to -0.71)	-1.06	(-2.26 to 0.13)
DBP	Hyperlipidemia	4	-1.55	(-2.71 to -0.39)	-2.42	(-4.03 to -0.80)	-2.34	(-3.61 to -1.07)	-1.80	(-3.18 to -0.43)	-1.21	(-3.54 to 1.13)
	No hyperlipidemia	55	-0.94	(-1.50 to -0.39)	-1.48	(-2.22 to -0.75)	-1.69	(-2.34 to -1.03)	-1.70	(-2.32 to -1.09)	-1.65	(-2.50 to -0.81)
Study duration, wk	in, wk											
SBP	≥12	29	-0.76	(-2.09 to 0.57)	-1.28	(-2.42 to -0.15)	-1.66	(-3.10 to -0.23)	-2.02	(-4.96 to 0.91)	-2.38	(-6.99 to 2.24)
	<12	41	-2.46	(-3.52 to -1.39)	-3.50	(-4.87 to -2.12)	-3.39	(-4.56 to -2.22)	-2.52	(-3.53 to -1.51)	-1.28	(-2.85 to 0.30)
DBP	≥12	29	-0.91	(-1.93 to 0.11)	-1.51	(-2.51 to -0.51)	-1.91	(-2.63 to -1.20)	-2.29	(-3.51 to -1.06)	-2.66	(-4.70 to -0.62)
	<12	40	-0.99	(-1.60 to -0.38)	-1.56	(-2.42 to -0.70)	-1.76	(-2.56 to -0.95)	-1.70	(-2.35 to -1.05)	-1.52	(-2.24 to -0.79)
Study design												
SBP	Crossover	7	-1.35	(-3.21 to 0.50)	-1.80	(-4.39 to 0.78)	-1.52	(-4.19 to 1.14)	-0.71	(-3.62 to 2.20)	0.44	(-3.54 to 4.41)
	Parallel	59	-1.95	(-2.75 to -1.16)	-2.75	(-3.78 to -1.71)	-2.67	(-3.61 to -1.73)	-2.20	(-3.14 to -1.25)	-1.68	(-2.90 to -0.46)
DBP	Crossover	=	-1.67	(-3.30 to -0.05)	-2.43	(-4.72 to -0.14)	-2.44	(-4.66 to -0.22)	-1.91	(-3.69 to -0.12)	-1.03	(-2.71 to 0.65)
	Parallel	58	-0.91	(-1.46 to -0.36)	-1.45	(-2.14 to -0.77)	-1.70	(-2.27 to -1.12)	-1.81	(-2.41 to -1.20)	-1.90	(-2.79 to -1.01)
Mean age, y												
SBP	≥45	35	-1.76	(-2.82 to -0.71)	-2.58	(-3.79 to -1.37)	-2.82	(-3.91 to -1.73)	-2.87	(-4.28 to -1.45)	-2.91	(-5.00 to -0.81)
	<45	21	-1.10	(-2.48 to 0.29)	-1.50	(-3.50 to 0.51)	-1.29	(-3.27 to 0.69)	-0.67	(-2.26 to 0.91)	0.14	(-1.04 to 1.33)
DBP	≥45	33	-0.61	(-1.26 to 0.04)	-1.17	(-1.93 to -0.40)	-1.68	(-2.31 to -1.05)	-2.18	(-2.85 to -1.51)	-2.68	(-3.66 to -1.70)
	21/2	00	CC T	110 01000	1 75	/ 0 00 + 0 0 EQ/	001	/ 2 2 K +2 (K 1)	101	100001200	0 20	1 1 2 4 +0 0 27

(Continued)

			1.0 g/d		2.0 g/d		3.0 g/d		4.0 g/d		5.0 g/d	
BP	Participants	No*	MD	(95% CI)	QW	(95% CI)	MD	(95% CI)	MD	(95% CI)	MD	(95% CI)
Fish oil composition	osition	_	-				-		-			-
SBP	Ethyl ester	12	-0.57	(-1.68 to 0.53)	-1.36	(-3.03 to 0.31)	-2.41	(-4.22 to -0.60)	-3.57	(-5.69 to -1.45)	-4.75	(-7.50 to -2.00)
	Fish oil	58	-1.97	(-2.76 to -1.18)	-2.71	(-3.74 to -1.68)	-2.49	(-3.43 to -1.55)	-1.70	(-2.65 to -0.74)	-0.72	(-2.06 to 0.63)
DBP	Ethyl ester	12	-1.1	(-1.64 to -0.58)	-1.69	(-2.40 to -0.98)	-1.84	(-2.49 to -1.19)	-1.73	(-2.36 to -1.10)	-1.53	(-2.39 to -0.66)
	Fish oil	57	-1.12	(-1.66 to -0.58)	-1.69	(-2.4 to -0.99)	-1.84	(-2.49 to -1.20)	-1.74	(-2.37 to -1.10)	-1.54	(-2.42 to -0.67)
Intervention type	ype											
SBP	Diet	00	-2.05	(-4.13 to 0.04)	-2.54	(-4.99 to -0.09)	-2.02	(-4.07 to 0.04)	-1.07	(-3.40 to 1.25)	-0.10	(-3.59 to 3.39)
	Supplementation	64	-1.78	(-2.53 to -1.03)	-2.58	(-3.59 to -1.57)	-2.62	(-3.59 to -1.65)	-2.24	(-3.22 to -1.25)	-1.75	(-3.02 to -0.47)
DBP	Diet	2	0.34	(-0.37 to 1.05)	-0.05	(-1.07 to 0.97)	-0.94	(-2.75 to 0.88)	-2.08	(-5.19 to 1.03)	-3.27	(-7.83 to 1.29)
	Supplementation	64	-1.16	(-1.69 to -0.63)	-1.76	(-2.45 to -1.06)	-1.90	(-2.51 to -1.29)	-1.78	(-2.35 to -1.22)	-1.60	(-2.39 to -0.82)
Sex												
SBP	Men	24	-1.28	(-2.32 to -0.23)	-2.12	(-3.89 to -0.36)	-2.19	(-4.10 to -0.28)	-1.59	(-3.18 to 0.00)	-0.54	(-1.70 to 0.62)
	Women	σ	1.37	(-6.26 to 9.00)	1.00	(-4.77 to 6.76)	-0.31	(-2.61 to 2.00)	-1.74	(-11.28 to 7.80)	-3.17	(-20.45 to 14.11)
DBP	Men	25	-1.13	(-1.71 to -0.55)	-1.89	(-2.85 to -0.93)	-2.01	(-3.03 to -1.00)	-1.60	(-2.46 to -0.75)	-0.85	(-1.63 to -0.07)
	Women	e	3.86	(-2.99 to 10.70)	2.39	(-3.04 to 7.82)	-1.92	(-5.90 to 2.05)	-6.62	(-16.60 to 3.36)	-11.32	(-28.27 to 5.63)
Individual effe	Individual effect of DHA or EPA											
SBP	DHA only	÷	-1.95	(-3.52 to -0.38)	-2.37	(-3.86 to -0.88)	-2.03	(-4.08 to 0.03)	-1.56	(-5.21 to 2.09)	-1.10	(-6.56 to 4.37)
	EPA only	9	1.42	(-2.52 to 5.35)	1.02	(-3.30 to 5.33)	-0.58	(-3.24 to 2.08)	-2.68	(-5.14 to -0.21)	-4.82	(-9.89 to 0.25)
DBP	DHA only	11	-1.10	(-3.06 to 0.86)	-1.04	(-2.66 to 0.57)	-0.40	(-2.03 to 1.23)	0.34	(-3.04 to 3.71)	1.07	(-4.35 to 6.50)
	EPA only	9	2.73	(1.72 to 3.74)	2.48	(1.27 to 3.68)	0.26	(-1.18 to 1.70)	-2.78	(-5.06 to -0.49)	-5.89	(-9.28 to -2.49)





Marginal average dose-response curve (solid line) with 95% point-wise CIs (dashed lines) estimated by a 1-stage randomeffects restricted cubic spline model, using 0 g/d as the referent. Studies included n=70 for systolic blood pressure (SBP) and n=69 for diastolic blood pressure (DBP).

an approximately linear relationship among those with hyperlipidemia for SBP, suggesting that increasing supplementation was associated with greater reductions in SBP. Again, this trend was not evident among those without hyperlipidemia for SBP, but an optimal intake of 2 g/d to 3 g/d could be seen. For DBP, there was also some indication that patients with hyperlipidemia may have greater reductions in DBP at 2 g/d to 3 g/d, compared with those without hyperlipidemia (Table, Figure 4).

We also found stronger effects among studies examining study participants with an average age of \geq 45 years (Table, Figure 5). The negligible departure from linearity between DHA+EPA and reductions in BP appeared to be limited to \geq 45 years in both SBP and DBP models, while studies in patients with a mean age of <45 years showed null effects. When examining by study duration, studies conducted <12 weeks tended to show stronger findings for SBP at 2 g/d to 3 g/d. However, in studies with a duration of \geq 12 weeks, DHA+EPA intake was found to lower BP in a fashion with a minor departure from linearity across the entire range of doses (Table, Figure S4). In a subgroup analysis stratified by study design (crossover versus parallel), we found slightly stronger effects among studies with a parallel design, in which relatively narrower Cls were estimated (Table, Figure S5).

We found no strong differences when stratifying by intervention type (diet versus supplementation), sex, and fish oil consumption (natural fish oil versus purified ethyl ester), possibly attributable to few studies that reported relationships for diet, women, and use of ethyl esters (Table, Figures S6 through S8). We retrieved few trials that evaluated DHA (n=11) or EPA (n=6) as individual fatty acids. There was insufficient statistical power to detect a meaningful difference between individual EPA and DHA on lowering either SBP or DBP (Table, Figure S9).

Risk of Study Bias and Publication Bias

One and 5 trials were ranked as high and moderate risk of bias, respectively, while the remainder of trials were ranked as low risk of bias (Table S4). Exclusion of moderate and high risk-of-bias trials did not appreciably change the shape of the dose-response curve (results not shown). The funnel plot and Egger regression test indicated asymmetry in the overall SBP model (z=-3.05, P=0.002). There was no evidence of plot asymmetry in pooled DBP and stratified models (Figures S10 and S11). This suggests that publication bias, if present because of small-study effects, did not strongly impact our overall findings. The leave-oneout sensitivity analyses in 1-stage regression models proved that overall effects were not driven by a small number of specific trials, but reflected the global effect of the included trials (Figures S12 and S13).

DISCUSSION

Using a new 1-stage strategy, we examined the strength and shape of the dose-response association between DHA+EPA intake and BP with up-to-date literature and multiple subgroup analyses. We found evidence of a J-shaped dose-response curve, where the greatest reductions of SBP and DBP occurred at moderate DHA+EPA doses between 2 g/d and 3 g/d. These findings were slightly stronger in studies where the average participant age was ≥45 years for SBP. We also found evidence of a stronger, approximately linear dose-response relationship among hyperlipidemic and hypertensive populations, suggesting that this is a population that could be more responsive to the beneficial impacts of ω3 PUFA intake on reductions in BP. Moreover, our data also demonstrated that w3 PUFA intake above the recommended intake of 3 g/d was not associated with additional benefits, particularly in normotensive subgroups.

Our findings are different from other metaanalyses that examined the relationship between ω 3




Figure 3. Dose-response relationship between changes in blood pressure and combined docosahexaenoic acid (DHA)+eicosapentaenoic acid (EPA) intake of the studies stratified by the baseline systolic blood pressure (SBP) level. Marginal average dose-response curve (solid line) with 95% point-wise CIs (dashed lines) estimated by a 1-stage random-effects restricted cubic spline model, using 0 g/d as the referent, in participants with baseline SBP \geq 130 mm Hg or <130 mm Hg. DBP indicates diastolic blood pressure; and n, number of the included study.

PUFA intake and changes in BP among RCT studies. Previous meta-analyses assumed a linear function.^{8,12} These studies found that BP reductions were not associated with DHA+EPA intake within a dose range of 0.2 g/d to 15 g/d. Morris et al⁷ attempted to test a dose-response effect with a meta-regression model with varying doses from 2 g/d to 6 g/d. They proposed a linear dose-response effect among the hypertensive studies, but the absence of doses between 7 g/d and 15 g/d seemed to put disproportionately more weight on the trial that used a dosage of 15 g/d. Similar to our study, Campbell et al¹⁰ later demonstrated that the BP-lowering effect was diminished with the increasing dose between 1 g/d and 6 g/d. Another effort was made a decade later by categorizing the ω 3 PUFA intake.¹¹ The stratum of 3 g/d to 4 g/d exerted the strongest effect of -3.85 mm Hg on SBP and -1.86 mm Hg on DBP, respectively, suggesting the existence of a dose threshold.¹¹ Overall, although they have been unable to smoothly shape the relationship between fish oil intake and BP over the entire range of exposure, these studies suggested

a nonlinear association and sparked further investigations. Our study builds on past evidence by examining the relationship using up-to-date literature, and novel methods that allow for the estimation of a nonlinear trend that accounts for the correlation between studies.

In our study, using overall and subgroup analyses we found a consistent J-shaped curve in our models. The optimal or threshold doses were estimated to fall between 2 g/d and 3 g/d in our models, which coincided with the range of EPA and DHA dose exhibiting maximal effects on BP.8,10,11 We also observed a minor departure from linearity of BP decline in participants with baseline SBP ≥130 mm Hg and a wider beneficial range in participants with hypertension compared with normotensive populations.^{8,11} Moreover, our findings are consistent with previous synthesized results in which DBP reductions were significantly greater in older populations (mean age ≥45 years) compared with younger populations.⁸ Considering cardiometabolic comorbidities, we further compared the effects of fish oil between participants with and those without hyperlipidemia. Our




Figure 4. Dose-response relationship between changes in blood pressure and combined docosahexaenoic acid (DHA)+eicosapentaenoic acid (EPA) intake of the studies stratified by the status of hyperlipidemia. Marginal average dose-response curve (solid line) with 95% point-wise CIs (dashed lines) estimated by a 1-stage random-effects restricted cubic spline model, using 0 g/d as the referent, in participants with or without hyperlipidemia. n indicates the number of the included study.

data suggested that ω 3 PUFA intake had larger reductions in SBP in populations with hyperlipidemia, which made our models more applicable given the increasing prevalence of metabolic syndromes.

Our analyses showed a positive and approximately linear (or L-shaped) dose-response association in respective subgroups of hypertensive, hyperlipidemic, and older participants. The approximately linear association could be interpreted as there is no dose threshold, particularly in the hypertensive subgroup. It is unclear why approximately linear associations were evident for these subgroups, in comparison to the Jshaped curves seen in the main analyses. It could be that high-risk population, such as those with hypertension and hyperlipidemia, could benefit differently from ω 3 PUFA intake supplementation in comparison to younger and healthier populations, particularly since ω3 PUFA is hypothesized to interact with many pathways, such as triglycerides, inflammation, and heart rate.^{25,26} Additionally, there could be mechanistic differences in bioavailability and efficacy of ω3 PUFA intake in these populations.^{25,26} However, given that few studies have investigated the relationship at higher doses (ie >7 g/d), more research is needed to elucidate this relationship, including biological mechanisms.

We are not the first to propose a nonlinear model for the dose-response of fish oil intake on the BP effect. The J-shaped dose-response effects have been tentatively proposed in prospective cohort studies and clinical trial meta-analyses. For example, summarized data of 6 selected independent prospective cohort studies indicated that there was also a J-shaped association between the increment of ω 3 PUFA intake and risk of hypertension within the low dose range of 0 g/d to 2 g/d.²⁷ A nonlinear negative and L-shaped association between ω 3 PUFA intake and the risk of hypertension was later proposed, with a dose at ≈3.4 g/d reaching the maximal BP risk-lowering effect in a cross-sectional study.²⁸ In these 2 reports, an apparent J-shaped relationship between ω 3 PUFA intake and hypertension risk was indicated with restricted cubic splines, a finding that is supported in our dose-response analysis examining changes in BP.

Our findings of a curvilinear relationship between BP effects and fish oil intake may have considerable implications in the cardioprotection of ω 3 PUFAs.




Figure 5. Dose-response relationship between changes in blood pressure and combined docosahexaenoic acid (DHA)+eicosapentaenoic acid (EPA) intake of the studies stratified by the mean of age.

Marginal average dose-response curve (solid line) with 95% point-wise CIs (dashed lines) estimated by a 1-stage random-effects restricted cubic spline model, using 0 g/d as the referent, among participants with a mean age \geq 45 years or <45 years. n indicates the number of the included study.

Given the moderate dose at 3 g/d, as shown in our dose-response relationship, both a fish oil diet or supplementation resulted in a decrease in BP \approx 2 mm Hg to 3 mm Hg in overall and most stratified effects. In 2009, the European Food Safety Authority recommended that an intake of EPA and DHA of \approx 3 g/d was required to bring out the claimed hypotensive effects.²⁹ Our findings seem to support this suggested daily dosage. Moreover, we found associations among both hypertensive and nonhypertensive groups, suggesting that ω 3 PUFAs intake could be beneficial for controlling BP even before the onset of hypertension. This means that the intake of ω 3 PUFAs could have implications on a person's future risk of stroke, ischemic heart disease,^{30,31} and all-cause mortality.³²

We recognize that there are some potential limitations to the conclusion that can be drawn from the current studies. The intrinsically significant variations among original trials, such as the device of BP measurement (automatic versus manual), the year of study (conducted 1987–2020), and the type of intervention (diet versus supplementation) are likely to bring some uncertainty to our results and potentially weaken the conclusion. Although we attempted to examine the influence of these factors on our overall findings in subgroup analyses, we acknowledge it is not possible to account for this heterogeneity directly in our analyses. Future research could benefit from examining a more biologically relevant exposure, such as the use of the absorbed DHA/EPA amount as the active exposure levels, use of standardized BP methods to ensure strict quality control, and further examination of how intervention type may influence the relationship. There are several other limitations. First, the absence of doses between 7 g/d and 15 g/d increases the uncertainty in the effect estimates at higher doses. However, the removal of these extreme data points did not strongly change our trends in overall and stratified effects. Second, we did not perform analyses based on the binary outcomes to predict the risk ratio because of the limited studies retrieved. Third, the mechanism of these J-shaped

relationships is not clear. The appearance of the response plateau might reflect a saturating status of fatty acid incorporation into the cell membrane.³³ The change point towards possibly increasing BP may indicate the enhanced α -adrenergic vasoconstriction³⁴ or disrupted ion exchanges.³⁵ Nevertheless, attention should be focused on the selection of optimal fish oil intake in the management of hypertension. Finally, because of the few available studies, we could not assess the impact of DHA+EPA on changes in BP by sex, DHA- or EPA-only, or diet-only effects. Future studies should further investigate these issues.

CONCLUSIONS

We conducted a dose-response meta-analysis to characterize the effects of DHA+EPA supplementation and dietary enrichment on BP levels using updated literature. This research helps to improve our understanding of the moderate effects of omega-3 fatty acids on BP reduction. The use of the new model suggests that an optimal dose of 3 g/d in overall and subgroup analyses may yield the greatest BP-lowering performance. The seemingly J-shaped associations between DHA+EPA dose and BP reduction in many subgroups might help reform preventive strategies for reducing cardiovascular risks in the general adult population. However, individuals who are at high risk for developing cardiovascular diseases, such as those with hypertension, may be more responsive to the beneficial impacts of ω 3 PUFA intake on reductions in BP.

ARTICLE INFORMATION

Received December 15, 2021; accepted March 24, 2022.

Affiliations

School of Pharmacy and State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, Macau, China (X.Z., N.Z., X.L.); and Department of Public Health Sciences and Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada (J.A.R., B.E.C.).

Sources of Funding

This work was supported by the Macau Science and Technology Development Fund (FDCT) (0123/2020/A and 0053/2021/A1) and the Faculty Research Grants of Macau University of Science and Technology (FRG-21-038-SP).

Disclosures

None.

Supplemental Material

Tables S1–S4 Figures S1–S13 References 36–104

REFERENCES

 Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet.* 2007;369:1090–1098. doi: 10.1016/S0140 -6736(07)60527-3

- Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med.* 2019;380:11–22. doi: 10.1056/NEJMoa1812792
- Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJ, Koenig W, McGuire DK, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268–2280. doi: 10.1001/ jama.2020.22258
- Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, Nilsen DW, Tveit A, Fagerland MW, Solheim S, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial. *Circulation*. 2021;143:528–539. doi: 10.1161/ CIRCULATIONAHA.120.052209
- Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. *JAMA*. 2012;308:1024–1033. doi: 10.1001/2012.jama.11374
- Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. *JAMA Cardiol.* 2018;3:225–234. doi: 10.1001/jamacardio.2017.5205
- Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. *Circulation*. 1993;88:523–533. doi: 10.1161/01.cir.88.2.523
- Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20:1493–1499. doi: 10.1097/00004872-200208000-00010
- Cabo J, Alonso R, Mata P. Omega-3 fatty acids and blood pressure. Br J Nutr. 2012;107:S195–S200. doi: 10.1017/S0007114512001584
- Campbell F, Dickinson HO, Critchley JA, Ford GA, Bradburn M. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. *Eur J Prev Cardiol.* 2013;20:107–120. doi: 10.1177/2047487312437056
- Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. *Am J Hypertens*. 2014;27:885–896. doi: 10.1093/ajh/hpu024
- Appel LJ, Miller ER III, Seidler AJ, Whelton PK. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. *Arch Intern Med.* 1993;153:1429–1438. doi: 10.1001/archinte.1993.00410120017003
- Crippa A, Discacciati A, Bottai M, Spiegelman D, Orsini N. One-stage dose-response meta-analysis for aggregated data. *Stat Methods Med Res.* 2019;28:1579–1596. doi: 10.1177/0962280218773122
- Filippini T, Naska A, Kasdagli MI, Torres D, Lopes C, Carvalho C, Moreira P, Malavolti M, Orsini N, Whelton PK, et al. Potassium intake and blood pressure: a dose-response meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9:e015719. doi: 10.1161/JAHA.119.015719
- Filippini T, Malavolti M, Whelton PK, Naska A, Orsini N, Vinceti M. Blood pressure effects of sodium reduction: dose-response metaanalysis of experimental studies. *Circulation*. 2021;143:1542–1567. doi: 10.1161/CIRCULATIONAHA.120.050371
- Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366. doi: 10.1136/bmj.I4898
- Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). *Cochrane Database Syst Rev.* 2022. Available from www.training.cochrane.org/handbook
- Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1–48.
- Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. *Am J Epidemiol.* 2012;175:66–73. doi: 10.1093/aje/kwr265

- 20. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2018;138:e426–e483. doi: 10.1161/CIR.0000000000000597
- Crippa A, Orsini N. Multivariate dose-response meta-analysis: the dosresmeta R package. J Stat Softw. 2016;72:1–15. doi: 10.18637/jss. v072.c01
- Orsini N. Weighted mixed-effects dose-response models for tables of correlated contrasts. *The Stata Journal: Promoting communications* on statistics and Stata. 2021;21:320–347. doi: 10.1177/15368 67x21 1025798
- Knapp HR, FitzGerald GA. The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. *N Engl J Med.* 1989;320:1037–1043. doi: 10.1056/ nejm198904203201603
- Levinson PD, Iosiphidis AH, Saritelli AL, Herbert PN, Steiner M. Effects of n-3 fatty acids in essential hypertension. *Am J Hypertens*. 1990;3:754–760. doi: 10.1093/ajh/3.10.754
- Stanton AV, James K, Brennan MM, O'Donovan F, Buskandar F, Shortall K, El-Sayed T, Kennedy J, Hayes H, Fahey AG, et al. Omega-3 index and blood pressure responses to eating foods naturally enriched with omega-3 polyunsaturated fatty acids: a randomized controlled trial. *Sci Rep.* 2020;10:15444. doi: 10.1038/s41598-020-71801-5
- Maki KC. Long-chain omega-3 fatty acid bioavailability: implications for understanding the effects of supplementation on heart disease risk. *J Nutr.* 2018;148:1701–1703. doi: 10.1093/jn/nxy205
- Yang B, Shi MQ, Li ZH, Yang JJ, Fish LD. Long-chain n-3 PUFA and Incidence of elevated blood pressure: a meta-analysis of prospective cohort studies. *Nutrients*. 2016;8:58. doi: 10.3390/nu8010058
- Chen J, Sun B, Zhang D. Association of dietary n3 and n6 fatty acids intake with hypertension: NHANES 2007–2014. *Nutrients*. 2019;11:1232. doi: 10.3390/nu11061232
- Grynberg A. Hypertension prevention: from nutrients to (fortified) foods to dietary patterns. Focus on fatty acids. *J Hum Hypertens*. 2005;19:S25–S33. doi: 10.1038/sj.jhh.1001957
- Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. *JAMA*. 2002;288:1882–1888. doi: 10.1001/jama.288.15.1882
- Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective SC. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360:1903–1913. doi: 10.1016/s0140 -6736(02)11911-8
- Li ZH, Zhong WF, Liu S, Kraus VB, Zhang YJ, Gao X, Lv YB, Shen D, Zhang XR, Zhang PD, et al. Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study. *BMJ*. 2020;368:m456. doi: 10.1136/bmj.m456
- Schuchardt JP, Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2013;89:1–8. doi: 10.1016/j.plefa.2013.03.010
- Kenny D, Brooks HL, Warltier DC. Enhanced alpha-adrenergic vasoconstriction by n-3 fatty acids in conscious dogs. *Am J Physiol.* 1990;258:H1660–H1667. doi: 10.1152/ajpheart.1990.258.6.H1660
- Singh TU, Garg SK, Mishra SK. Evaluation of effects of eicosapentaenoic acid on Na(+)-K(+)-ATPase in sheep pulmonary artery. *Hum Exp Toxicol.* 2012;31:579–587. doi: 10.1177/0960327111417909
- Albert BB, Derraik JG, Brennan CM, Biggs JB, Garg ML, Cameron-Smith D, Hofman PL, Cutfield WS. Supplementation with a blend of krill and salmon oil is associated with increased metabolic risk in overweight men. *Am J Clin Nutr.* 2015;102:49–57. doi: 10.3945/ ajcn.114.103028
- Armstrong P, Kelley DS, Newman JW, Staggers FE Sr, Hartiala J, Allayee H, Stephensen CB. Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans. J Nutr. 2012;142:1417–1428. doi: 10.3945/jn.112.159814
- Bach R, Schmidt U, Jung F, Kiesewetter H, Hennen B, Wenzel E, Schieffer H, Bette L, Heyden S. Effects of fish oil capsules in two

dosages on blood pressure, platelet functions, haemorheological and clinical chemistry parameters in apparently healthy subjects. *Ann Nutr Metab.* 1989;33:359–367. doi: 10.1159/000177559

- Barcelo-Coblijn G, Murphy EJ, Othman R, Moghadasian MH, Kashour T, Friel JK. Flaxseed oil and fish-oil capsule consumption alters human red blood cell n-3 fatty acid composition: a multiple- dosing trial comparing 2 sources of n-3 fatty acid. *Am J Clin Nutr.* 2008;88:801–809. doi: 10.1093/ajcn/88.3.801
- Blonk MC, Bilo HJ, Nauta JJ, Popp-Snijders C, Mulder C, Donker AJ. Dose-response effects of fish-oil supplementation in healthy volunteers. Am J Clin Nutr. 1990;52:120–127. doi: 10.1093/ajcn/52.1.120
- Bonaa KH, Bjerve KS, Straume B, Gram IT, Thelle D. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. A population-based intervention trial from the Tromso study. *N Engl J Med.* 1990;322:795–801. doi: 10.1056/NEJM19900322322 1202
- Buckley JD, Burgess S, Murphy KJ, Howe PR. DHA-rich fish oil lowers heart rate during submaximal exercise in elite Australian Rules footballers. *J Sci Med Sport*. 2009;12:503–507. doi: 10.1016/j. jsams.2008.01.011
- Burgin-Maunder CS, Brooks PR, Hitchen-Holmes D, Russell FD. Moderate dietary supplementation with omega-3 fatty acids does not impact plasma von Willebrand factor profile in mildly hypertensive subjects. *Biomed Res Int.* 2015;2015:1–8. doi: 10.1155/2015/394871
- Carter JR, Schwartz CE, Yang H, Joyner MJ. Fish oil and neurovascular control in humans. *Am J Physiol Heart Circ Physiol.* 2012;303:H450–H456. doi: 10.1152/ajpheart.00353.2012
- Chin JP, Gust AP, Nestel PJ, Dart AM. Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. *Hypertension*. 1993;21:22–28. doi: 10.1161/01.hyp.21.1.22
- Cobiac L, Clifton PM, Abbey M, Belling GB, Nestel PJ. Lipid, lipoprotein, and hemostatic effects of fish vs fish-oil n-3 fatty acids in mildly hyperlipidemic males. *Am J Clin Nutr.* 1991;53:1210–1216. doi: 10.1093/ajcn/53.5.1210
- Cobiac L, Nestel PJ, Wing LM, Howe PR. A low-sodium diet supplemented with fish oil lowers blood pressure in the elderly. *J Hypertens*. 1992;10:87–92. doi: 10.1097/00004872-199201000-00014
- Conquer JA, Cheryk LA, Chan E, Gentry PA, Holub BJ. Effect of supplementation with dietary seal oil on selected cardiovascular risk factors and hemostatic variables in healthy male subjects. *Thromb Res.* 1999;96:239–250. doi: 10.1016/s0049-3848(99)00106-1
- Dart AM, Riemersma RA, Oliver MF. Effects of Maxepa on serum lipids in hypercholesterolaemic subjects. *Atherosclerosis*. 1989;80:119–124. doi: 10.1016/0021-9150(89)90019-1
- Demke DM, Peters GR, Linet OI, Metzler CM, Klott KA. Effects of a fish oil concentrate in patients with hypercholesterolemia. *Atherosclerosis*. 1988;70:73–80. doi: 10.1016/0021-9150(88)90101-3
- Derosa G, Maffioli P, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Randazzo S, Cicero AF. Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. *Expert Opin Pharmacother*. 2009;10:1239–1247. doi: 10.1517/14656560902865601
- Derosa G, Cicero AF, Fogari E, D'Angelo A, Bonaventura A, Romano D, Maffioli P. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol. 2012;6:553–564. doi: 10.1016/j.jacl.2012.02.010
- Dewell A, Marvasti FF, Harris WS, Tsao P, Gardner CD. Low- and high-dose plant and marine (n-3) fatty acids do not affect plasma inflammatory markers in adults with metabolic syndrome. *J Nutr.* 2011;141:2166–2171. doi: 10.3945/jn.111.142240
- Dyerberg J, Eskesen DC, Andersen PW, Astrup A, Buemann B, Christensen JH, Clausen P, Rasmussen BF, Schmidt EB, Tholstrup T, et al. Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study. *Eur J Clin Nutr.* 2004;58:1062–1070. doi: 10.1038/sj.ejcn.1601934
- Flaten H, Hostmark AT, Kierulf P, Lystad E, Trygg K, Bjerkedal T, Osland A. Fish-oil concentrate: effects on variables related to cardiovascular disease. *Am J Clin Nutr.* 1990;52:300–306. doi: 10.1093/ ajcn/52.2.300
- Geelen A, Zock PL, Swenne CA, Brouwer IA, Schouten EG, Katan MB. Effect of n-3 fatty acids on heart rate variability and baroreflex sensitivity in middle-aged subjects. *Am Heart J.* 2003;146:E4. doi: 10.1016/ S0002-8703(03)00441-1

- Grieger JA, Miller MD, Cobiac L. Investigation of the effects of a high fish diet on inflammatory cytokines, blood pressure, and lipids in healthy older Australians. *Food Nutr Res.* 2014;58: doi: 10.3402/fnr. v58.20369
- Grimsgaard S, Bonaa KH, Hansen JB, Myhre ES. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. *Am J Clin Nutr.* 1998;68:52–59. doi: 10.1093/ ajcn/68.1.52
- Grundt H, Nilsen DW, Hetland O, Aarsland T, Baksaas I, Grande T, Woie L. Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia. *J Intern Med.* 1995;237:249–259. doi: 10.1111/j.1365-2796.1995.tb01173.x
- Hallund J, Madsen BO, Bugel SH, Jacobsen C, Jakobsen J, Krarup H, Holm J, Nielsen HH, Lauritzen L. The effect of farmed trout on cardiovascular risk markers in healthy men. *Br J Nutr.* 2010;104:1528–1536. doi: 10.1017/S0007114510002527
- Harris WS, Lemke SL, Hansen SN, Goldstein DA, DiRienzo MA, Su H, Nemeth MA, Taylor ML, Ahmed G, George C. Stearidonic acidenriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker. *Lipids*. 2008;43:805–811. doi: 10.1007/s1174 5-008-3215-0
- Hellsten G, Boman K, Saarem K, Hallmans G, Nilsson TK. Effects on fibrinolytic-activity of corn- oil and a fish-oil preparation enriched with omega-3-polyunsaturated fatty-acids in a long- term study. *Curr Med Res Opin*. 1993;13:133–139. doi: 10.1185/03007999309111542
- Hill AM, Buckley JD, Murphy KJ, Howe PR. Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. *Am J Clin Nutr.* 2007;85:1267– 1274. doi: 10.1093/ajcn/85.5.1267
- Howe PR, Evans HM, Kuszewski JC, Wong RH. Effects of long chain omega-3 polyunsaturated fatty acids on brain function in mildly hypertensive older adults. *Nutrients*. 2018;10:1413. doi: 10.3390/nu101 01413
- Huerta AE, Navas-Carretero S, Prieto-Hontoria PL, Martinez JA, Moreno-Aliaga MJ. Effects of alpha-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss. *Obesity* (*Silver Spring*). 2015;23:313–321. doi: 10.1002/oby.20966
- Hughes GS, Ringer TV, Watts KC, DeLoof MJ, Francom SF, Spillers CR. Fish oil produces an atherogenic lipid profile in hypertensive men. *Atherosclerosis.* 1990;84:229–237. doi: 10.1016/0021-9150(90)90095 -Z
- Jones PJ, Senanayake VK, Pu S, Jenkins DJ, Connelly PW, Lamarche B, Couture P, Charest A, Baril-Gravel L, West SG, et al. DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial. *Am J Clin Nutr.* 2014;100:88–97. doi: 10.3945/ ajcn.113.081133
- Kelley DS, Siegel D, Vemuri M, Mackey BE. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. *Am J Clin Nutr.* 2007;86:324–333. doi: 10.1093/ajcn/86.2.324
- Kestin M, Clifton P, Belling GB, Nestel PJ. n-3 fatty acids of marine origin lower systolic blood pressure and triglycerides but raise LDL cholesterol compared with n-3 and n-6 fatty acids from plants. *Am J Clin Nutr.* 1990;51:1028–1034. doi: 10.1093/ajcn/51.6.1028
- Kristensen S, Schmidt EB, Schlemmer A, Rasmussen C, Lindgreen E, Johansen MB, Christensen JH. The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: a randomised, double-blind, placebo- controlled trial. *Lipids Health Dis.* 2016;15:216. doi: 10.1186/s1294 4-016-0382-5
- Lee JB, Notay K, Klingel SL, Chabowski A, Mutch DM, Millar PJ. Docosahexaenoic acid reduces resting blood pressure but increases muscle sympathetic outflow compared with eicosapentaenoic acid in healthy men and women. *Am J Physiol Heart Circ Physiol*. 2019;316:H873–H881. doi: 10.1152/ajpheart.00677.2018
- Lindqvist HM, Langkilde AM, Undeland I, Sandberg AS. Herring (Clupea harengus) intake influences lipoproteins but not inflammatory and oxidation markers in overweight men. *Br J Nutr.* 2009;101:383– 390. doi: 10.1017/S0007114508003073
- Lofgren RP, Wilt TJ, Nichol KL, Crespin L, Pluhar R, Eckfeldt J. The effect of fish oil supplements on blood pressure. *Am J Public Health*. 1993;83:267–269. doi: 10.2105/ajph.83.2.267

- Logan SL, Spriet LL. Omega-3 fatty acid supplementation for 12 weeks increases resting and exercise metabolic rate in healthy communitydwelling older females. *PLoS One*. 2015;10:e0144828. doi: 10.1371/ journal.pone.0144828
- Maki KC, Reeves MS, Farmer M, Griinari M, Berge K, Vik H, Hubacher R, Rains TM. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. *Nutr Res.* 2009;29:609–615. doi: 10.1016/j.nutres.2009.09.004
- Meland E, Fugelli P, Laerum E, Rønneberg R, Sandvik L. Effect of fish oil on blood pressure and blood lipids in men with mild to moderate hypertension. *Scand J Prim Health Care*. 1989;7:131–135. doi: 10.3109/02813438909087229
- Mills DE, Mah M, Ward RP, Morris BL, Floras JS. Alteration of baroreflex control of forearm vascular resistance by dietary fatty acids. *Am J Physiol.* 1990;259:R1164–1171. doi: 10.1152/ajpregu.1990.259.6.R1164
- Monahan KD, Wilson TE, Ray CA. Omega-3 fatty acid supplementation augments sympathetic nerve activity responses to physiological stressors in humans. *Hypertension*. 2004;44:732–738. doi: 10.1161/01. HYP.0000145292.38579.f4
- Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. *Hypertension*. 1999;34:253–260. doi: 10.1161/01.hyp.34.2.253
- Murphy KJ, Meyer BJ, Mori TA, Burke V, Mansour J, Patch CS, Tapsell LC, Noakes M, Clifton PA, Barden A, et al. Impact of foods enriched with n-3 long-chain polyunsaturated fatty acids on erythrocyte n-3 levels and cardiovascular risk factors. *Br J Nutr.* 2007;97:749–757. doi: 10.1017/S000711450747252X
- Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL. Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. *J Nutr.* 2011;141:207–213. doi: 10.3945/ jn.110.130021
- Nestel P, Shige H, Pomeroy S, Cehun M, Abbey M, Raederstorff D. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. *Am J Clin Nutr.* 2002;76:326–330. doi: 10.1093/ajcn/76.2.326
- Noreen EE, Brandauer J. The effects of supplemental fish oil on blood pressure and morning cortisol in normotensive adults: a pilot study. J Complement Integr Med. 2012;9. doi: 10.1515/1553-3840.1467
- Pase MP, Grima N, Cockerell R, Stough C, Scholey A, Sali A, Pipingas A. The effects of long-chain omega-3 fish oils and multivitamins on cognitive and cardiovascular function: a randomized, controlled clinical trial. *J Am Coll Nutr.* 2015;34:21–31. doi: 10.1080/07315 724.2014.880660
- Passfall J, Philipp T, Woermann F, Quass P, Thiede M, Haller H. Different effects of eicosapentaenoic acid and olive oil on blood pressure, intracellular free platelet calcium, and plasma lipids in patients with essential hypertension. *Clin Investig.* 1993;71:628–633. doi: 10.1007/BF00184490
- Prisco D, Paniccia R, Bandinelli B, Filippini M, Francalanci I, Giusti B, Giurlani L, Gensini GF, Abbate R, Neri Serneri GG. Effect of mediumterm supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. *Thromb Res.* 1998;91:105–112. doi: 10.1016/s0049-3848(98)00046-2
- Radack K, Deck C, Huster G. The effects of low doses of n-3 fatty acid supplementation on blood pressure in hypertensive subjects. A randomized controlled trial. *Arch Intern Med.* 1991;151:1173–1180. doi: 10.1001/archinte.1991.00400060097017
- Ryu J, Lerner J, Sullivan JM. Unresponsiveness of forearm hemodynamics to omega-3 polyunsaturated fatty acids and aspirin. *Prostaglandins*. 1990;39:339–347. doi: 10.1016/0090-6980(90)90051 -v
- Sagara M, Njelekela M, Teramoto T, Taguchi T, Mori M, Armitage L, Birt N, Birt C, Yamori Y. Effects of docosahexaenoic Acid supplementation on blood pressure, heart rate, and serum lipids in Scottish men with hypertension and hypercholesterolemia. *Int J Hypertens*. 2011;2011:1– 7. doi: 10.4061/2011/809198
- Sanders TA, Gleason K, Griffin B, Miller GJ. Influence of an algal triacylglycerol containing docosahexaenoic acid (22: 6n–3) and docosapentaenoic acid (22: 5n–6) on cardiovascular risk factors in healthy men and women. *Br J Nutr.* 2006;95:525–531. doi: 10.1079/bjn20 051658

- Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT, Chowienczyk PJ. Effect of low doses of long- chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. *Am J Clin Nutr.* 2011;94:973–980. doi: 10.3945/ajcn.111.018036
- Shabrina A, Tung TH, Nguyen NT, Lee HC, Wu HT, Wang W, Huang SY. n-3 PUFA and caloric restriction diet alters lipidomic profiles in obese men with metabolic syndrome: a preliminary open study. *Eur J Nutr.* 2020;59:3103–3112. doi: 10.1007/s00394-019-02149-4
- Shen T, Xing G, Zhu J, Zhang S, Cai Y, Li D, Xu G, Xing E, Rao J, Shi R. Effects of 12-week supplementation of marine omega-3 PUFAbased formulation omega3q10 in older adults with prehypertension and/or elevated blood cholesterol. *Lipids Health Dis.* 2017;16:253. doi: 10.1186/s12944-017-0617-0
- 94. Sjoberg NJ, Milte CM, Buckley JD, Howe PR, Coates AM, Saint DA. Dose-dependent increases in heart rate variability and arterial compliance in overweight and obese adults with DHA-rich fish oil supplementation. *Br J Nutr.* 2010;103:243–248. doi: 10.1017/S000711450 999153X
- Stark KD, Holub BJ. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. *Am J Clin Nutr.* 2004;79:765–773. doi: 10.1093/ajcn/79.5.765
- Sveinsdottir K, Martinsdottir E, Ramel A. Blood pressure-lowering effects of long chain n-3 fatty acids from meals enriched with liquid fish oil and from microencapsulated powder. *Int J Food Sci Nutr.* 2016;67:1017–1023. doi: 10.1080/09637486.2016.1208733
- 97. Theobald HE, Goodall AH, Sattar N, Talbot DC, Chowienczyk PJ, Sanders TA. Low-dose docosahexaenoic acid lowers diastolic blood

pressure in middle-aged men and women. J Nutr. 2007;137:973–978. doi: 10.1093/jn/137.4.973

- Toft I, Bonaa KH, Ingebretsen OC, Nordoy A, Jenssen T. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. A randomized, controlled trial. *Ann Intern Med.* 1995;123:911–918. doi: 10.7326/0003-4819-123-12-19951 2150-00003
- (THPCRG) ToHPCRG. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the trials of hypertension prevention, phase I. *JAMA*. 1992;267:1213–1220. doi: 10.1001/jama.1992.03480090061028
- Vandongen R, Mori TA, Burke V, Beilin LJ, Morris J, Ritchie J. Effects on blood pressure of omega 3 fats in subjects at increased risk of cardiovascular disease. *Hypertension*. 1993;22:371–379. doi: 10.1161/01. hyp.22.3.371
- Vericel E, Calzada C, Chapuy P, Lagarde M. The influence of low intake of n-3 fatty acids on platelets in elderly people. *Atherosclerosis*. 1999;147:187–192. doi: 10.1016/s0021-9150(99)00171-9
- 102. von Houwelingen R, Nordoy A, van der Beek E, Houtsmuller U, de Metz M, Hornstra G. Effect of a moderate fish intake on blood pressure, bleeding time, hematology, and clinical chemistry in healthy males. *Am J Clin Nutr.* 1987;46:424–436. doi: 10.1093/ajcn/46.3.424
- Wang S, Ma AQ, Song SW, Quan QH, Zhao XF, Zheng XH. Fish oil supplementation improves large arterial elasticity in overweight hypertensive patients. *Eur J Clin Nutr.* 2008;62:1426–1431. doi: 10.1038/sj.ejcn.1602886
- 104. Wu SY, Mayneris-Perxachs J, Lovegrove JA, Todd S, Yaqoob P. Fishoil supplementation alters numbers of circulating endothelial progenitor cells and microparticles independently of eNOS genotype. *Am J Clin Nutr.* 2014;100:1232–1243. doi: 10.3945/ajcn.114.088880

SUPPLEMENTAL MATERIAL

Торіс	No.	Item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Line 1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist	
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Line 50-64
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Line 69-72
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Line 81-89
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Line 77-80
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Line 77-78 and Table S2
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Line 80-81
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Line 92-93
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Line 93-96
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Line 96-97
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Line 89-90

Table S1. Checklist: PRISMA 2020 Main Checklist.

Торіс	No.	Item	Location where item is reported
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Line 99-102
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item 5)).	Line 125-128, Table S3
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Line 107-108; Line 110-114
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Line 110-114
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Line 110-114 and Line 120-121
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Line 114-120
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Line 107-108
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Line 104-107
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	N/A
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Line 125-128 Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Line 125-128, Figure S1
Study characteristics	17	Cite each included study and present its characteristics.	Supp. references and Table S3
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table S4
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Line 129-149 and Table 1, S3
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Line 198-199

Торіс	No.	Item	Location where item is reported
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Line 151-196
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Line 168-196
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Line 203-205
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Line 198-203
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Line 151-166
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Line 208-262
	23b	Discuss any limitations of the evidence included in the review.	Line 263-273
	23c	Discuss any limitations of the review processes used.	Line 263-273
	23d	Discuss implications of the results for practice, policy, and future research.	Line 274-282
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	N/A
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	N/A
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/A
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Line 284-285
Competing interests	26	Declare any competing interests of review authors.	Line 286
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	N/A

PRIMSA Abstract Checklist

Торіс	No.	Item	Reported?
TITLE			
Title	1	Identify the report as a systematic review.	Yes
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	Yes
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	Yes
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	No
Synthesis of results	6	Specify the methods used to present and synthesize results.	Yes
RESULTS			
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Yes
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Yes
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	No
Interpretation	10	Provide a general interpretation of the results and important implications.	Yes
OTHER			
Funding	11	Specify the primary source of funding for the review.	No
Registration	12	Provide the register name and registration number.	No

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. MetaArXiv. 2020, September 14. DOI: 10.31222/osf.io/v7gm2. For more information, visit: www.prisma-statement.org

Table S2. Literature retrieval strategies for online databases.

Database	Search Strategy
PubMed	 #1 ("Dietary fats, unsaturated" [MH] OR "fish oils" [MH] OR "fish oil" [tiab] OR "fatty acids, omega-3"[MH] OR "Docosahexaenoic Acids" [tiab] OR "PUFA" [tiab] OR "DHA" [tiab] OR "EPA" [tiab] OR "long chain omega-3 fatty acids" [tiab] OR "polyunsaturated fatty acid" [tiab] OR "Docosahexaenoic Acids" [tiab] OR "eicosapentaenoic acid" [tiab]) #2 ("blood pressure"[MH] OR "blood pressure determination"[MH] OR "arterial pressure"[MH] OR "hypertension"[MH] OR "blood pressure"[tiab] OR "hypertension"[tiab]) #1 AND #2 AND "human study"
Embase	 #1 ('fish oils':ab,ti) OR ('omega-3 fatty acids':ab,ti) OR ('docosahexaenoic acids':ab,ti) OR ('PUFA':ab,ti) OR ('DHA':ab,ti) OR ('EPA':ab,ti) OR ('ALA':ab,ti) OR ('long chain omega-3 fatty acids':ab,ti) OR ('polyunsaturated fatty acid':ab,ti) OR ('eicosapentaenoic acid':ab,ti) OR ('alpha linolenic acid':ab,ti) #2 ('blood pressure':ab,ti) OR ('blood pressure determination':ab,ti) OR ('arterial pressure':ab,ti) OR ('hypertension':ab,ti) #1 AND #2 AND 'human'/de

Author	Year	Country	n, M/F	Age ^a , y Mean (SE/SD) range	Design	HTN	HL	Device	Intervention type	DHA dose d/day	EPA dose d/day	Total dose d/day	Control	Duration, week
Albert ³⁶	2015	Australia	M47	35-55	Crossover	No	No	Automatic	Supplementation	0.15	0.23	0.38	Canola oil	8
Armstrong 37	2012	United States	M35/F81	20-59	Parallel	No	No	Automatic	Supplementation	1.00	2.00	3.00	Corn + soy oil	6
Bach ³⁸	1989	United States	M16/F14	31(9)	Parallel	No	Yes	NR	Supplementation	1.44	1.08	2.52	Neutral oil	5
Barcelo-Coblijn ³⁹	2008	Canada	MF62	36-44	Parallel	No	No	NR	Supplementation	0.13	0.25	0.38	Sunflower oil	12
					Parallel	No	No	NR	Supplementation	0.25	0.50	0.76	Sunflower oil	12
Blonk ⁴⁰	1990	Netherland	M45	22-48	Parallel	No	No	Manual	Supplementation	0.60	0.90	1.50	Not specified	12
					Parallel	No	No	Manual	Supplementation	1.20	1.80	3.00	Not specified	12
					Parallel	No	No	Manual	Supplementation	2.40	3.60	6.00	Not specified	12
Bonaa ⁴¹	1990	Netherland	MF156	20-61	Parallel	Yes	No	Automatic	Supplementation	1.82	3.26	5.08	Corn oil	10
Buckley ⁴²	2009	Australia	M25	22(1)	Parallel	No	No	Automatic	Supplementation	1.56	0.36	1.92	Sunflower oil	5
Burgin-Maunder ⁴³	2015	Australia	M23/F19	45-58	Parallel	No	No	Automatic	Supplementation	0.84	1.68	2.52	Canola oil	12
					Parallel	Yes	No	Automatic	Supplementation	0.84	1.68	2.52	Canola oil	12
Carter ⁴⁴	2012	United States	M18/F20	24(2)	Parallel	No	No	Automatic	Supplementation	1.10	1.60	2.70	Olive oil	8
Chin ⁴⁵	1993	Australia	M29	18-32	Parallel	No	No	Manual	Supplementation	0.58	0.89	1.47	Palm+safflow er+olive oil	4
					Parallel	No	No	Manual	Supplementation	1.16	1.78	2.94	Palm+safflow er+olive oil	4
					Parallel	No	No	Manual	Supplementation	2.32	3.56	5.88	Palm+safflow er+olive oil	4
Cobiac ⁴⁶	1991	Australia	M31	30-60	Parallel	No	Yes	Automatic	Diet	3.00	1.50	4.50	Vegetable oil	5
					Parallel	No	Yes	Automatic	Supplementation	1.74	3.08	4.82	Vegetable oil	5
Cobiac ⁴⁷	1992	Australia	M36/F19	60-80	Parallel	No	No	Automatic	Supplementation	1.70	2.50	4.20	Sunflower oil	4
Conquer ⁴⁸	1999	Canada	M19	30(2)	Parallel	No	No	NR	Supplementation	1.70	1.30	3.00	Vegetable oil	6
Dart ⁴⁹	1989	United Kingdom	M14/F7	46(2)	Crossover	No	Yes	NR	Supplementation	2.50	3.52	6.02	Olive oil	8.5
Demke ⁵⁰	1988	United States	M8/F23	18-60	Parallel	No	Yes	NR	Supplementation	0.79	0.93	1.72	Safflower oil	4
Derosa ⁵¹	2009	Italy	M164/F169	≥18	Parallel	No	Yes	Manual	Supplementation	1.50	0.90	2.40	Sucrose, mannitol and mineral salt	26
Derosa ⁵²	2012	Italy	M82/F85	18-75	Parallel	No	Yes	NR	Supplementation	1.35	1.20	2.55	Sucrose, mannitol and mineral salt	26

Table S3. Summary of study characteristics of 71 trials.

Dewell ⁵³	2011	United States	M64/F36	50(10)	Parallel	No	No	NR	Supplementation	0.50	0.70	1.20	Soybean oil	6
					Parallel	No	No	NR	Supplementation	1.50	2.10	3.60	Soybean oil	6
Dyerberg ⁵⁴	2004	Denmark	M51	20-60	Parallel	No	No	Automatic	Supplementation	1.40	2.20	3.60	Palm oil	8
Flaten ⁵⁵	1990	Norway	M56	35-45	Parallel	No	No	Manual	Supplementation	2.87	3.60	6.47	Olive oil	6
Geelen ⁵⁶	2003	Netherland	M36/F38	50-70	Parallel	No	No	Automatic	Supplementation	0.56	0.70	1.26	Sunflower oil	12
Grieger ⁵⁷	2014	Australia	MF80	70(6)	Parallel	No	No	Automatic	Diet	NR	NR	0.80	Usual diet	8
Grimsgaard ⁵⁸	1998	Norway	M234	36-56	Parallel	No	No	Automatic	Supplementation	_	3.80	3.80	Corn oil	7
					Parallel	No	No	Automatic	Supplementation	3.60	—	3.60	Corn oil	7
Grundt ⁵⁹	1995	Norway	M51/F6	18-70	Parallel	No	Yes	Manual	Supplementation	1.28	2.07	3.35	Corn oil	12
Hallund ⁶⁰	2010	Denmark	M45	40-70	Parallel	No	No	Automatic	Diet	2.00	0.90	2.90	Chicken	8
Harris ⁶¹	2008	United States	M9/F13	21-70	Parallel	No	No	NR	Supplementation	-	0.98	0.98	Soybean oil	16
Hellsten ⁶²	1993	Sweden	MF40	30-60	Parallel	No	Yes	NR	Supplementation	NR	NR	2.00	Corn oil	21
Hill ⁶³	2007	Australia	M28/F53	25–65	Parallel	Yes	Yes	Automatic	Supplementation	1.56	0.36	1.92	Sunflower oil	12
Howe ⁶⁴	2018	Australia	M26/F12	40-85	Parallel	Yes	No	Automatic	Supplementation	1.60	0.40	2.00	Corn oil	20
Huerta ⁶⁵	2015	Spain	F77	20-50	Parallel	No	No	Manual	Supplementation	0.04	1.30	1.34	Sunflower oil	10
Hughes ⁶⁶	1990	United States	M13	32(9)	Crossover	No	No	Automatic	Supplementation	1.50	3.50	5.00	Wheat germ oil	4.3
					Crossover	Yes	No	Automatic	Supplementation	1.50	3.50	5.00	Wheat germ oil	4.3
Jones ⁶⁷	2014	United States and Canada	M60/F70	46(14)	Crossover	No	No	Automatic	Supplementation	0.35	0.01	0.36	Oleic acid	4
Kelley ⁶⁸	2007	United States	M34	39-66	Parallel	No	Yes	Automatic	Supplementation	3.00	—	3.00	Olive oil	14
Kestin ⁶⁹	1990	Australia	M33	46(2)	Parallel	No	No	Automatic	Supplementation	1.30	2.10	3.40	Linoleic acid	6
Knapp ²³	1989	United States	M36	30-71	Parallel	Yes	No	Automatic	Supplementation	1.20	1.80	3.00	Safflower oil	4
					Parallel	Yes	No	Automatic	Supplementation	6.00	9.00	15.00	Safflower oil	4
Kristensen ⁷⁰	2016	Denmark	M60/F83	52(12)	Parallel	No	No	Automatic	Supplementation	1.50	1.50	3.00	Olive oil	24
Lee ⁷¹	2019	Canada	M45/F45	18-30	Parallel	No	No	Automatic	Supplementation	-	0.81	0.81	Olive oil	12
					Parallel	No	No	Automatic	Supplementation	0.81	-	0.81	Olive oil	12
Levinson ²⁴	1990	United States	MF17	18-75	Parallel	Yes	No	Automatic	Supplementation	6.00	9.00	15.00	Vegetable oil	6
Lindqvist ⁷²	2009	Sweden	M35	35-60	Crossover	No	No	NR	Diet	NR	NR	1.20	Baked lean pork + chicken	6
Lofgren ⁷³	1993	United States	M23	≤60	Crossover	No	No	Manual	Supplementation	2.40	3.60	6.00	Safflower oil	12
					Crossover	Yes	No	Manual	Supplementation	2.40	3.60	6.00	Safflower oil	12

Logan ⁷⁴	2015	Canada	F26	60-76	Parallel	No	No	Automatic	Supplementation	1.00	2.00	3.00	Olive oil	12
Maki ⁷⁵	2009	United States	M13/F63	35-64	Parallel	No	No	Automatic	Supplementation	0.09	0.22	0.31	Olive oil	4
					Parallel	No	No	Automatic	Supplementation	0.18	0.21	0.39	Olive oil	4
Meland ⁷⁶	1989	Norway	M40	26-66	Parallel	Yes	No	Manual	Supplementation	2.40	3.60	6.00	Corn + olive oil	6
Mills ⁷⁷	1990	Canada	M29	19-31	Parallel	No	No	Automatic	Supplementation	0.51	0.81	1.32	Safflower oil	4
Monahan ⁷⁸	2004	United States	M10/F8	18-35	Parallel	No	No	Automatic	Supplementation	2.00	3.00	5.00	Olive oil	4
Mori ⁷⁹	1999	Australia	M56	20-65	Parallel	No	Yes	Automatic	Supplementation	-	3.84	3.84	Olive oil	6
					Parallel	No	Yes	Automatic	Supplementation	3.68	-	3.68	Olive oil	6
Murphy ⁸⁰	2007	Australia	M41/F43	20-65	Parallel	No	No	Automatic	Diet	0.60	0.40	1.00	Control diet	26
Neff ⁸¹	2011	United States	M15/F21	18-65	Parallel	No	No	Automatic	Supplementation	2.00	-	2.00	Corn + soybean oil	16
Nestel ⁸²	2002	Australia	M21/F17	40-69	Parallel	No	Yes	Automatic	Supplementation	-	3.04	3.04	Olive oil	7
					Parallel	No	Yes	Automatic	Supplementation	2.83	—	2.83	Olive oil	7
Noreen ⁸³	2012	United States	M14/F26	19-55	Parallel	No	No	Automatic	Supplementation	0.80	1.60	2.40	Safflower oil	6
Pase ⁸⁴	2015	Australia	M75/F85	50-70	Parallel	No	No	Automatic	Supplementation	0.48	0.48	0.96	Monounsatura ted acid	16
Passfall ⁸⁵	1993	Germany	M4/F6	40-61	Crossover	Yes	No	Automatic	Supplementation	0.90	1.26	2.16	Olive oil	6
Prisco ⁸⁶	1998	Italy	M16	33-56	Parallel	Yes	No	Automatic	Supplementation	1.40	2.04	3.44	Olive oil	17
Radack ⁸⁷	1991	United States	M19/F14	≥18	Crossover	Yes	No	Manual	Supplementation	0.80	1.20	2.00	Safflower oil	12
Ryu ⁸⁸	1990	United States	M20	20-39	Parallel	No	No	Manual	Supplementation	0.90	2.10	3.00	Wheat germ oil	4
Sagara ⁸⁹	2011	United Kingdom	M38	45-59	Parallel	Yes	Yes	Automatic	Supplementation	2.00	-	2.00	Olive oil bread	5
Sanders ⁹⁰	2006	United Kingdom	M39/F40	33	Parallel	No	No	Automatic	Supplementation	1.50	-	1.50	Olive oil	4
Sanders ⁹¹	2011	United Kingdom	M142/F225	45-70	Parallel	No	No	Automatic	Supplementation	0.18	0.27	0.45	Olive oil	52
					Parallel	No	No	Automatic	Supplementation	0.36	0.54	0.90	Olive oil	52
					Parallel	No	No	Automatic	Supplementation	0.72	1.08	1.80	Olive oil	52
Shabrina ⁹²	2020	China	M21	>30	Parallel	Mixed	No	Automatic	Supplementation	0.85	1.28	2.13	Caloric restriction	12
Shen ⁹³	2017	China	M48/F49	63(10)	Parallel	No	No	NR	Supplementation	0.20	0.31	0.51	Soybean oil	12
Sjoberg ⁹⁴	2010	Australia	M36/F31	53(2)	Parallel	No	No	Automatic	Supplementation	0.52	0.10	0.62	Sunola oil	12
					Parallel	No	No	Automatic	Supplementation	1.04	0.20	1.24	Sunola oil	12
					Parallel	No	No	Automatic	Supplementation	1.56	0.30	1.86	Sunola oil	12

Stark ⁹⁵	2004	Canada	F32	45-70	Crossover	No	No	Automatic	Supplementation	2.80	—	2.80	Corn and soy oil	4
Sveinsdottir ⁹⁶	2016	Iceland	M30/F69	>50	Parallel	Mixed	No	NR	Diet	0.50	1.00	1.50	Olive oil	4
Theobald ⁹⁷	2007	United Kingdom	M20/F19	45-65	Crossover	No	No	NR	Supplementation	0.70	-	0.70	Olive oil	13
Toft ⁹⁸	1995	Norway	M50/F28	21-61	Parallel	Yes	No	Manual	Supplementation	1.20	2.10	3.30	Corn oil	16
TOHP ⁹⁹	1992	United States	MF350	30-54	Parallel	No	No	Manual	Supplementation	0.90	2.10	3.00	Olive oil	24
Vandongen ¹⁰⁰	1993	Australia	M51	30-60	Parallel	No	No	Automatic	Supplementation	0.90	1.30	2.20	Olive, palm, safflower oils	12
					Parallel	No	No	Automatic	Supplementation	1.70	2.60	4.30	Olive, palm, safflower oils	12
					Parallel	No	No	Automatic	Diet	0.90	1.30	2.20	Olive, palm, safflower oils	12
Vericel ¹⁰¹	1999	France	MF20	70-83	Parallel	Yes	No	NR	Supplementation	0.15	0.03	0.18	Sunflower oil	6
von Houwelingen ¹⁰²	1987	Norway and Netherland	M82	20-45	Parallel	No	No	Manual	Diet	3.00	1.70	4.70	Meat paste	6
Wang ¹⁰³	2008	China	M37/F6	42(3)	Parallel	Yes	Yes	Manual	Supplementation	0.36	0.54	0.90	Vegetable oil	8
Wu ¹⁰⁴	2014	United Kingdom	M29/F55	21-65	Crossover	No	No	Automatic	Supplementation	0.60	0.90	1.50	Corn oil	8

Abbreviations: DHA, docosahexaenoic acid; DBP, diastolic blood pressure; EPA, eicosapentaenoic acid; HTN, hypertension; HL, hyperlipidemia; NR, not reported; —, not administered.

Note: a, The age is expressed as Mean (SD/SE), SD, standard deviation and SE, standard error.

Author	Year	Randomiz- ation	Blinding	Missing outcome	Measure- ment	Selection of results	Overall
Albert ³⁶	2015	low	low	low	low	low	low
Armstrong ³⁷	mstrong ³⁷ 2012		some concern	low	low	low	low
Bach ³⁸	1989	some concern	low	low	some concern	low	low
Barcelo-Coblijn ³⁹	2008	some concern	some concern	low	some concern	low	low
Blonk ⁴⁰	1990	some concern	medium	low moderate		some concern	moderate
Bonaa ⁴¹	1990	low	low	low	low	low	low
Buckley ⁴²	2009	some concern	some concern	low	low	low	low
Burgin-Maunder ⁴³	2015	some concern	some concern	low	some concern	low	low
Carter ⁴⁴	2012	some concern	some concern	low	low	low	low
Chin ⁴⁵	1993	some concern	some concern	low	low	low	low
Cobiac ⁴⁶	1991	low	some concern	low	low	low	low
Cobiac ⁴⁷	1992	some concern	some concern	low	low	low	low
Conquer ⁴⁸	1999	moderate	some concern	low	some concern	low	moderate
Dart ⁴⁹	1989	moderate	some concern	low	some concern	low	moderate
Demke ⁵⁰	1988	some concern	low	low	some concern	low	low
Derosa ⁵¹	2009	low	low	low	low	low	low
Derosa ⁵²	2012	low	some concern	low	some concern	low	low
Dewell ⁵³	2011	some concern	low	low	some concern	low	low
Dyerberg ⁵⁴	2004	low	some concern	low	some concern	low	low
Flaten ⁵⁵	1990	some concern	some concern	low	low	low	low
Geelen ⁵⁶	2003	some concern	some concern	low	some concern	low	low
Grieger ⁵⁷	2014	some concern	low	low	low	low	low
Grimsgaard ⁵⁸	1998	low	some concern	low	low	low	low
Grundt ⁵⁹	1995	some concern	high	low	low	low	low
Hallund ⁶⁰	2010	low	low	low	low	low	low
Harris ⁶¹	2008	some concern	some concern	some concern	some concern	low	moderate
Hellsten ⁶²	1993	some concern	low	low	some concern	low	low
Hill ⁶³	2007	low	low	low	low	low	low
Howe ⁶⁴	2018	some concern	some concern	low	low	low	low
Huerta ⁶⁵	2015	low	some concern	some concern	some concern	low	moderate
Hughes ⁶⁶	1990	some concern	low	low	low	low	low
Jones ⁶⁷	2014	low	low	low	some concern	low	low
Kelley ⁶⁸	2007	some concern	low	low	some concern	low	low
Kestin ⁶⁹	1990	some concern	low	some concern	low	low	low
Knapp ²³	1989	low	low	low	low	low	low
Kristensen ⁷⁰	2016	low	low	low	some concern	low	low
Lee ⁷¹	2019	some concern	low	low	low	low	low
Levinson ²⁴	1990	some concern	high	low	low	low	low
Lindqvist ⁷²	2009	some concern	some concern	low	some concern	low	low

Table S4.	Risk of bias of included trials.
	Hish of blub of merudea criais.

Lofgren ⁷³	1993	some concern	medium	low	low	low	low
Logan ⁷⁴	2015	some concern	some concern	low	low	low	low
Maki ⁷⁵	2009	some concern	some concern	low	low	low	low
Meland ⁷⁶	1989	some concern	low	low	low	low	low
Mills ⁷⁷	1990	low	some concern	low	low	low	low
Monahan ⁷⁸	2004	some concern	low	low	low	low	low
Mori ⁷⁹	1999	some concern	low	low	low	low	low
Murphy ⁸⁰	2007	some concern	some concern	low	low	low	low
Neff ⁸¹	2011	some concern	some concern	low	some concern	low	low
Nestel ⁸²	2002	low	some concern	low	some concern	low	low
Noreen ⁸³	2012	some concern	low	low	some concern	low	low
Pase ⁸⁴	2015	low	some concern	low	low	low	low
Passfall ⁸⁵	1993	some concern	some concern	low	low	low	low
Prisco ⁸⁶	1998	some concern	low	low	low	some concern	low
Radack ⁸⁷	1991	low	some concern	low	low	low	low
Ryu ⁸⁸	1990	low	some concern	low	low	low	low
Sagara ⁸⁹	2011	some concern	low	low	some concern	low	low
Sanders ⁹⁰	2006	low	low	low	low	low	low
Sanders ⁹¹	2011	some concern	some concern	low	low	low	low
Shabrina ⁹²	2020	some concern	low	low	some concern	low	low
Shen ⁹³	2017	low	some concern	low	some concern	low	low
Sjoberg ⁹⁴	2010	some concern	low	low	low	low	low
Stark ⁹⁵	2004	low	some concern	low	low	low	low
Sveinsdottir ⁹⁶	2016	some concern	low	low	low	low	low
Theobald ⁹⁷	2007	some concern	low	low	low	low	low
Toft ⁹⁸	1995	low	low	low	low	low	low
TOHP ⁹⁹	1992	some concern	some concern	low	low	low	low
Vandongen ¹⁰⁰	1993	some concern	high	low	low	low	low
Vericel ¹⁰¹	1999	high	medium	low	some concern	low	high
von Houwelingen ¹⁰²	1987	some concern	some concern	low	low	low	low
Wang ¹⁰³	2008	some concern	some concern	low	low	low	low
Wu ¹⁰⁴	2014	low	low	low	low	low	low

Note: Two review authors independently assessed risk of bias of each included trials in the domains of randomization (random sequence generation); blinding (allocation concealment, blinding of participants and personnel, and blinding of outcome assessors); missing outcome (incomplete outcome data); measurement (method and measurement bias); and selection of results (reporting bias).

Figure S1. Histogram of dose and duration distribution. A, Histogram of trial duration (week). B, Histogram of the total dose (DHA+EPA, g/day).





Figure S2. Dose-response relation between changes in blood pressure and combined DHA+EPA intake, after excluding the two trials with a dose of 15 g/day.



Marginal average dose-response curve (solid line) with 95% point-wise confidence intervals (dashed lines) estimated by a one-stage random-effects restricted cubic spline model, using 0 g/day as the referent. DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; SBP, systolic blood pressure. Studies included N=69 for SBP and N=68 for DBP.




Figure S3. Dose-response relation between changes in blood pressure and combined DHA+EPA intake of the studies stratified by the status of hypertension

Marginal average dose-response curve (solid line) with 95% point-wise confidence intervals (dashed lines) estimated by a one-stage random-effects restricted cubic spline model, using 0 g/day as the referent, in participants with or with on hypertension, baseline SBP \geq 140 mmHg or DBP \geq 90 mmHg. DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; SBP, systolic blood pressure. N, number of the included study.




Figure S4. Dose-response relation between changes in blood pressure and combined DHA+EPA intake of the studies stratified by trial duration.

Marginal average dose-response curve (solid line) with 95% point-wise confidence intervals (dashed lines) estimated by a one-stage random-effects restricted cubic spline model, using 0 g/day as the referent, in participants with trial duration \geq or <12 weeks. DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; SBP, systolic blood pressure. N, number of the included study.




Figure S5. Dose-response relation between changes in blood pressure and combined DHA+EPA intake in studies stratified by study design.

Marginal average dose-response curve (solid line) with 95% point-wise confidence intervals (dashed lines) estimated by a one-stage random-effects restricted cubic spline model, using 0 g/day as the referent, in studies stratified by study design (crossover or parallel). DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; SBP, systolic blood pressure. N, number of the included study.






Figure S6. Dose-response relation between changes in blood pressure and combined DHA+EPA intake of the studies stratified by the intervention type.

Marginal average dose-response curve (solid line) with 95% point-wise confidence intervals (dashed lines) estimated by a one-stage random-effects restricted cubic spline model, using 0 g/day as the referent, in studies restricted to different intervention types (diet-based or supplementation). DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; SBP, systolic blood pressure. N, number of the included study.





Marginal average dose-response curve (solid line) with 95% point-wise confidence intervals (dashed lines) estimated by a one-stage random-effects restricted cubic spline model, using 0 g/day as the referent, among female- or male-only participants. DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; SBP, systolic blood pressure. N, number of the included study.






Figure S8.Dose-response relation between changes in blood pressure and combined DHA+EPA intake of the studies stratified by the fish oil composition.


Marginal average dose-response curve (solid line) with 95% point-wise confidence intervals (dashed lines) estimated by a one-stage random-effects restricted cubic spline model, using 0 g/day as the referent, in studies either using purified ethyl esters or natural fish oils. DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; SBP, systolic blood pressure. N, number of the included study.





Marginal average dose-response curve (solid line) with 95% point-wise confidence intervals (dashed lines) estimated by a one-stage random-effects restricted cubic spline model, using 0 g/day as the referent, in studies using DHA or EPA alone. DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; SBP, systolic blood pressure. N, number of the included study.

Figure S10. Funnel plot for assessment of overall publication bias.



Estimated number of missing studies: 0 ; Test for funnel plot asymmetry: z = -1.38, p = 0.17

The plots are generated for the mean difference of changes in systolic (SBP) and diastolic (DBP) blood pressure levels as mmHg and its standard error using the trim-and-fill method. No imputed studies are predicted in both plots. Filled dots indicate observed studies. The Grey area indicates $p \le 0.05$. The plot asymmetry analysis was performed by Egger's regression test.

Figure S11. Funnel plot for assessment of publication bias in studies with stratification of hypertension status.

0


2.682

5.364


-10

Estimated number of missing studies: 0;

Standard Error



Estimated number of missing studies: 0 ; Test for funnel plot asymmetry: z = -1.08, p = 0.28



Estimated number of missing studies: 4 ; Test for funnel plot asymmetry: z = 0.14, p = 0.89

Non-Hypertension-DBP

-5

Test for funnel plot asymmetry: z = -1.70, p = 0.09


0

Mean Difference

5

10

Non-Hypertension-SBP



Estimated number of missing studies: 0; Test for funnel plot asymmetry: z = -0.63, p = 0.53

The plots are generated for the mean difference of changes in systolic (SBP) and diastolic (DBP) blood pressure levels as mmHg and its standard error using the trim-and-fill method for studies divided by hypertension status. Imputed studies are shown as empty dots. Solid dots indicate observed studies. The Grey area indicates $p \le 0.05$. The asymmetry analysis was performed by Egger's regression test.





Figure S12. Sensitivity analysis of overall effects of EPA+DHA on SBP.

Sensitivity analysis of mean difference for changes in systolic blood pressure (SBP) levels between DHA+EPA treatment and placebo groups, using the leave-one-out method where each time one study is omitted to compute the pooled estimate in the one-stage regression model.





Sensitivity analysis of mean difference for changes in diastolic blood pressure (DBP) levels between DHA+EPA treatment and placebo groups, using the leave-one-out method where each time one study is omitted to compute the pooled estimate in the one-stage regression model.